CN112384219A - Sumo-激活酶抑制剂和抗cd20抗体的施用 - Google Patents

Sumo-激活酶抑制剂和抗cd20抗体的施用 Download PDF

Info

Publication number
CN112384219A
CN112384219A CN201980044629.7A CN201980044629A CN112384219A CN 112384219 A CN112384219 A CN 112384219A CN 201980044629 A CN201980044629 A CN 201980044629A CN 112384219 A CN112384219 A CN 112384219A
Authority
CN
China
Prior art keywords
administered
antibody
compound
pharmaceutically acceptable
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980044629.7A
Other languages
English (en)
Chinese (zh)
Inventor
S·M·K·普鲁库里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN112384219A publication Critical patent/CN112384219A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980044629.7A 2018-07-09 2019-07-08 Sumo-激活酶抑制剂和抗cd20抗体的施用 Pending CN112384219A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695630P 2018-07-09 2018-07-09
US62/695,630 2018-07-09
PCT/US2019/040838 WO2020014139A1 (en) 2018-07-09 2019-07-08 Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies

Publications (1)

Publication Number Publication Date
CN112384219A true CN112384219A (zh) 2021-02-19

Family

ID=69142959

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980044629.7A Pending CN112384219A (zh) 2018-07-09 2019-07-08 Sumo-激活酶抑制剂和抗cd20抗体的施用

Country Status (11)

Country Link
US (1) US12097199B2 (https=)
EP (1) EP3820475A4 (https=)
JP (1) JP7352582B2 (https=)
KR (1) KR20210031679A (https=)
CN (1) CN112384219A (https=)
AU (1) AU2019300852A1 (https=)
BR (1) BR112021000169A2 (https=)
CA (1) CA3105947A1 (https=)
MX (1) MX2021000349A (https=)
TW (1) TW202019422A (https=)
WO (1) WO2020014139A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020176643A1 (en) * 2019-02-26 2020-09-03 Millennium Pharmaceuticals, Inc. Compounds useful as adjuvants
WO2021203001A1 (en) * 2020-04-03 2021-10-07 Millennium Pharmaceuticals, Inc. Method of treating patients infected with a viral infection with an inhibitor of small ubiquitin like modifier activating enzyme
BR112022023137A2 (pt) * 2020-05-15 2023-02-07 Takeda Pharmaceuticals Co Administração de inibidor de enzima de ativação de sumo e anticorpos anti-cd38
WO2025029578A1 (en) * 2023-08-03 2025-02-06 Duke University Sumoylation as a therapeutic target in inflammatory bowel diseases and infections disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1729203A (zh) * 2002-10-17 2006-02-01 根马布股份公司 抗cd20的人单克隆抗体
WO2010043582A1 (en) * 2008-10-17 2010-04-22 Santaris Pharma A/S Method for the treatment of cancer
CN103288835A (zh) * 2006-02-02 2013-09-11 千禧药品公司 E1活化酶抑制剂
CN106999479A (zh) * 2014-07-01 2017-08-01 米伦纽姆医药公司 可用作sumo活化酶抑制剂的杂芳基化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2340091C (en) 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
WO2010044892A1 (en) 2008-10-17 2010-04-22 President And Fellows Of Harvard College Diagnostic method based on large scale identification of post-translational modification of proteins
US9434765B2 (en) 2011-05-24 2016-09-06 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune High affinity SUMO traps
JP6378759B2 (ja) 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物
JP7126941B2 (ja) 2015-12-22 2022-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
KR20210131316A (ko) * 2019-02-27 2021-11-02 밀레니엄 파머슈티컬스 인코퍼레이티드 Sumo-활성화 효소 저해제 및 관문 저해제의 투여

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1729203A (zh) * 2002-10-17 2006-02-01 根马布股份公司 抗cd20的人单克隆抗体
CN103288835A (zh) * 2006-02-02 2013-09-11 千禧药品公司 E1活化酶抑制剂
WO2010043582A1 (en) * 2008-10-17 2010-04-22 Santaris Pharma A/S Method for the treatment of cancer
CN106999479A (zh) * 2014-07-01 2017-08-01 米伦纽姆医药公司 可用作sumo活化酶抑制剂的杂芳基化合物

Also Published As

Publication number Publication date
MX2021000349A (es) 2021-05-14
TW202019422A (zh) 2020-06-01
JP7352582B2 (ja) 2023-09-28
KR20210031679A (ko) 2021-03-22
JP2021532067A (ja) 2021-11-25
US20210267972A1 (en) 2021-09-02
BR112021000169A2 (pt) 2021-04-06
EP3820475A4 (en) 2022-04-13
CA3105947A1 (en) 2020-01-16
AU2019300852A1 (en) 2021-01-07
US12097199B2 (en) 2024-09-24
WO2020014139A1 (en) 2020-01-16
EP3820475A1 (en) 2021-05-19

Similar Documents

Publication Publication Date Title
JP6525474B2 (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
US12403154B2 (en) Administration of sting agonist and checkpoint inhibitors
US12097199B2 (en) Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies
KR20240082379A (ko) 암 치료 방법 및 이의 약제학적 조성물
CN113473989B (zh) Sumo活化酶抑制剂和检查点抑制剂的施用
KR20230010659A (ko) Sumo-활성화 효소 억제제 및 항-cd38 항체의 투여
RU2830077C2 (ru) Введение ингибитора sumo-активирующего фермента и ингибиторов контрольных точек
WO2023073645A1 (en) Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20211115

Address after: Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: MILLENNIUM PHARMACEUTICALS, Inc.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210219